These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9218931)

  • 1. Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment.
    Koch KM; Liu M; Davis IM; Shaw S; Yin Y
    Eur J Clin Pharmacol; 1997; 52(3):229-34. PubMed ID: 9218931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation.
    Wells TG; Heulitt MJ; Taylor BJ; Fasules JW; Kearns GL
    J Clin Pharmacol; 1998 May; 38(5):402-7. PubMed ID: 9602950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
    Madani S; Kauffman R; Simpson P; Lehr VT; Lai ML; Sarniak A; Tolia V
    J Clin Pharmacol; 2014 Feb; 54(2):201-5. PubMed ID: 24258773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate.
    Koch KM; Kerr BM; Gooding AE; Davis IM
    Br J Clin Pharmacol; 1996 Aug; 42(2):207-11. PubMed ID: 8864319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ranitidine in patients with renal failure.
    Garg DC; Baltodano N; Jallad NS; Perez G; Oster JR; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1986 Apr; 26(4):286-91. PubMed ID: 3700684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ranitidine in patients undergoing haemofiltration.
    Gladziwa U; Krishna DR; Klotz U; Ittel TH; Schunkert H; Glöckner WM; Mann H
    Eur J Clin Pharmacol; 1988; 35(4):427-30. PubMed ID: 3197752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children.
    Lugo RA; Harrison AM; Cash J; Sweeley J; Vernon DD
    Crit Care Med; 2001 Apr; 29(4):759-64. PubMed ID: 11373465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers.
    Tsuruoka S; Sugimoto KI; Hayasaka T; Saito T; Fujimura A
    Eur J Clin Pharmacol; 2000 Nov; 56(8):581-3. PubMed ID: 11151748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
    James LP; Stowe CD; Farrar HC; Menendez AA; Argao EA
    J Clin Pharmacol; 1999 Dec; 39(12):1242-7. PubMed ID: 10586389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.
    Gladziwa U; Klotz U
    Clin Pharmacokinet; 1993 Apr; 24(4):319-32. PubMed ID: 8098275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of ranitidine after burn injury.
    Martyn JA; Bishop AL; Oliveri MF
    Clin Pharmacol Ther; 1992 Apr; 51(4):408-14. PubMed ID: 1563210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate.
    Koch KM; Davis IM; Gooding AE; Yin Y
    Br J Clin Pharmacol; 1996 Aug; 42(2):201-5. PubMed ID: 8864318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
    Lin JH
    Clin Pharmacokinet; 1991 Mar; 20(3):218-36. PubMed ID: 1673880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog.
    Boom SP; Meyer I; Wouterse AC; Russel FG
    Biopharm Drug Dispos; 1998 Apr; 19(3):199-208. PubMed ID: 9570004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
    Sica DA; Comstock T; Harford A; Eshelman F
    Eur J Clin Pharmacol; 1987; 32(6):587-91. PubMed ID: 3653228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ranitidine and nizatidine in very elderly patients.
    Sasaki M; Sudoh T; Fujimura A
    Am J Ther; 2005; 12(3):223-5. PubMed ID: 15891265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of renal function on the pharmacokinetics of ranitidine.
    Dixon JS; Borg-Costanzi JM; Langley SJ; Lacey LF; Toon S
    Eur J Clin Pharmacol; 1994; 46(2):167-71. PubMed ID: 8039538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration.
    Lachman L; Howden CW
    Am J Gastroenterol; 2000 Jan; 95(1):57-61. PubMed ID: 10638559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers.
    Flores Pérez J; Juárez Olguín H; Flores Pérez C; Pérez Guillé G; Guillé Pérez A; Camacho Vieyra A; Toledo López A; Carrasco Portugal M; Lares Asseff I
    Chronobiol Int; 2003 May; 20(3):485-94. PubMed ID: 12868543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.